OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23rd 2021

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

September 23rd 2021

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Dr. Kahl on a Potential Limitation of Frontline BTK Inhibitor Combos in MCL

September 22nd 2021

Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.

Dr. Hubbard on the Barriers of Widely Implementing ctDNA ​Testing in CRC

September 22nd 2021

Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

September 21st 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Dr. Cohen on Mitigation Strategies for CAR T-Cell Therapy in Multiple Myeloma

September 21st 2021

Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.

Dr. Raghav on Regorafenib Dose Optimization in CRC

September 21st 2021

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCL

September 20th 2021

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Dr. Wainberg on the Need for Continued Enrollment to Clinical Trials in CRC

September 20th 2021

Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.

Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

Dr. Rugo on Overall Survival With First-Line Pembrolizumab in Metastatic TNBC

September 19th 2021

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.

Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

September 18th 2021

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

September 18th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

September 17th 2021

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

September 17th 2021

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Dr. Van Rhee on the Clinical Implications of CAR T-Cell Therapy in Relapsed/Refractory Myeloma

September 17th 2021

Frits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr. Baljevic on the FDA Approval of the ICARIA-MM Regimen in Relapsed/Refractory Multiple Myeloma

September 16th 2021

Muhamed Baljevic, MD, discusses the FDA approval of isatuximab-irfc in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma.

Dr. Wang on the Significance of p53 Mutations in MCL

September 16th 2021

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

NEXT PAGE
PREVIOUS PAGE